Cellestia Biotech AG   Report issue

For profit Phase 2
Founded: Lausanne Switzerland (2014)

Organization Overview

First Clinical Trial
2017
NCT03422679
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Cellestia Biotech AG

Active Ingredients

Drugs in Phase 2 Trials (3)

abemaciclib (verzenio) (1 trial)

cb-103 (3 trials)

lenvatinib (lenvima) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Carcinoma, Adenoid Cystic (Phase 2)

Cholangiocarcinoma (Phase 2)

Glomus Tumor (Phase 2)

Hematologic Neoplasms (Phase 2)

Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 3